Related Experiment Videos
Aggregation-Dependent interaction of the Alzheimer's beta-amyloid and microglia
F Muehlhauser1, U Liebl, S Kuehl
1Department of Neurology, University of Heidelberg, Mannheim, Germany.
Abstract:
Chronic glial activation possibly plays a role in chronic neurodegeneration in Alzheimer's disease (AD). It has been shown that amyloid peptide is capable of activating microglial cells in vitro. The aim of this study was to further characterize the structural preconditions for amyloid peptide in order to activate glial cells and to investigate whether this peptide is also able to induce glial activation in the living brain. We observed that amyloid peptide induced strong cellular activation in primary microglial cell culture as detected by the release of stable metabolites of nitric oxide (NO), when the peptide was fibrillar. For this activation, co-stimulation with interferon-gamma was a precondition. Using microdialysis of the living brain in a rat we observed pronounced NO generation when fibrillar amyloid peptide was stereotaxically injected. Non-fibrillar amyloid peptide did not induce such a glial reaction. No administration of interferon-gamma or any other co-stimulatory factor was necessary in vivo. Thus, we show that fibrillar, but not non-fibrillar amyloid peptide induced glial activation also in vivo. In the case of the living brain, the presence of deposits of fibrillar amyloid peptide could maintain a chronic microglial activation, ultimately leading to the progressive neurodegeneration associated with Alzheimer's disease.
Insights
Fibrillar amyloid peptide, but not non-fibrillar, activates glial cells. This fibrillar form can drive chronic microglial activation in the brain, potentially contributing to Alzheimer's disease neurodegeneration.
Area of Science:
- Neuroscience
- Immunology
Background:
- Chronic glial activation is implicated in neurodegenerative diseases like Alzheimer's disease (AD).
- Amyloid peptide is known to activate microglial cells, the primary immune cells of the brain, in laboratory settings.
Purpose of the Study:
- To determine the structural requirements of amyloid peptide for glial cell activation.
- To investigate if amyloid peptide can induce glial activation within a living brain.
Main Methods:
- Studied glial cell activation in primary microglial cultures by measuring nitric oxide (NO) release.
- Utilized in vivo microdialysis in rats to assess NO generation after amyloid peptide injection into the brain.
- Compared the effects of fibrillar and non-fibrillar amyloid peptide.
Main Results:
- Fibrillar amyloid peptide induced significant glial activation in vitro, requiring co-stimulation with interferon-gamma.
- Stereotactic injection of fibrillar amyloid peptide into the rat brain led to pronounced NO generation.
- Non-fibrillar amyloid peptide did not elicit a glial response in vivo, and no co-stimulatory factors were needed.
Conclusions:
- Fibrillar amyloid peptide, unlike its non-fibrillar form, directly induces glial activation in the living brain.
- Deposits of fibrillar amyloid peptide may sustain chronic microglial activation, a key factor in Alzheimer's disease progression and neurodegeneration.